These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 27315562)
41. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. Hornberger J; Hirth RA Am J Kidney Dis; 2012 Aug; 60(2):280-7. PubMed ID: 22560829 [TBL] [Abstract][Full Text] [Related]
42. A quarter century of medicare expenditures for ESRD. Eggers PW Semin Nephrol; 2000 Nov; 20(6):516-22. PubMed ID: 11111852 [TBL] [Abstract][Full Text] [Related]
43. Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism. Gupta C; Chertow GM; Linthicum MT; Van Nuys K; Belozeroff V; Quarles D; Lakdawalla DN Health Serv Res; 2014 Dec; 49(6):1925-43. PubMed ID: 25040130 [TBL] [Abstract][Full Text] [Related]
44. Cost, work, reimbursement, and the pediatric nephrologist in the United States Medicare/End-Stage Renal Disease Program. Arnold W; Alexander S Pediatr Nephrol; 1997 Apr; 11(2):250-7. PubMed ID: 9090676 [TBL] [Abstract][Full Text] [Related]
46. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace. Lowrie EG; Hampers CL N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710 [TBL] [Abstract][Full Text] [Related]
47. Important legal, regulatory issues impacting renal care in 2008. Riley J; Pristave R Nephrol News Issues; 2008 Dec; 22(13):48-9. PubMed ID: 19149317 [No Abstract] [Full Text] [Related]
48. Impact of capitation on free-standing dialysis facilities: can you survive? McMurray SD; Miller J Am J Kidney Dis; 1997 Oct; 30(4):542-8. PubMed ID: 9328370 [TBL] [Abstract][Full Text] [Related]
49. Medicare and erythropoietin. Steinbrook R N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449 [No Abstract] [Full Text] [Related]
50. The first DRG: lessons from the end stage renal disease program for the prospective payment system. Maxwell JH; Sapolsky HM Inquiry; 1987; 24(1):57-67. PubMed ID: 2951335 [TBL] [Abstract][Full Text] [Related]
51. Implications of the End-Stage Renal Disease Treatment Choices Model among U.S. Dialysis Providers. Paulus AB; Howard AD; Vinson BA Nephrol Nurs J; 2021; 48(1):11-17. PubMed ID: 33683840 [TBL] [Abstract][Full Text] [Related]
52. Surviving change: Can the ESRD provisions in the SCHIP create a level playing field? Gardner AV Nephrol News Issues; 2007 Sep; 21(10):52-3. PubMed ID: 17918480 [No Abstract] [Full Text] [Related]
53. Freestanding Dialysis Facility Quality Incentive Program Scores and Mortality Among Incident Dialysis Patients in the United States. Ajmal F; Probst JC; Brooks JM; Hardin JW; Qureshi Z; Jafar TH Am J Kidney Dis; 2020 Feb; 75(2):177-186. PubMed ID: 31685294 [TBL] [Abstract][Full Text] [Related]
54. Kidney Failure? Dialysis is the only medical service without automatic inflation updates from Medicare. Some people are trying to change that. Zigmond J Mod Healthc; 2006 Nov; 36(44):6-7, 14-6, 1. PubMed ID: 17128943 [TBL] [Abstract][Full Text] [Related]
55. Financing of end-stage renal disease care: past, present, and future. Farley DO Adv Ren Replace Ther; 1994 Apr; 1(1):24-31. PubMed ID: 7641085 [TBL] [Abstract][Full Text] [Related]
56. Who should be paying for vitamin D analogues--Medicare or the patients? Hall G Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205 [No Abstract] [Full Text] [Related]
57. Savings drainer. Bundled dialysis payments targeted in latest deal. Kutscher B Mod Healthc; 2013 Jan; 43(1):8-9, 16. PubMed ID: 23495412 [No Abstract] [Full Text] [Related]
58. The costs of dialysis in the USA. Garella S Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223 [TBL] [Abstract][Full Text] [Related]
59. Medicare payment options for recombinant erythropoietin therapy. Sisk JE; Gianfrancesco FD; Coster JM Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):93-7. PubMed ID: 1928087 [TBL] [Abstract][Full Text] [Related]
60. Epidemiology of end stage renal disease and implications for public policy. Rubin RJ Public Health Rep; 1984; 99(5):492-8. PubMed ID: 6435162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]